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Quantitative PCRCervical cancer is the second most frequent cancer in women worldwide and is associated with genetic alter-
ations, infection with human papilloma virus (HPV), angiogenesis and inﬂammatory processes. The idea that in-
ﬂammation is involved in tumorigenesis is supported by the frequent appearance of cancer in areas of chronic
inﬂammation. On the other hand, the inﬂammatory response is controlled by the action of anti-inﬂammatory
mediators, among these mediators, annexin A1 (ANXA1), a 37 kDa protein was detected as a modulator of in-
ﬂammatory processes and is expressed by tumor cells.
The study was carried out on the epithelial cancer cell line (SiHa) treated with the peptide of annexin A1
(ANXA1Ac2-26). We combined subtraction hybridization approach, Ingenuity Systems software and quantitative
PCR, in order to evaluate gene expression inﬂuenced by ANXA1.
We observed that ANXA1Ac2-26 inhibited proliferation in SiHa cells after 72 h. In these cells, 55 genes exhibited
changes in expression levels in response to peptide treatment. Six geneswere selected and the expression results
of 5 up-regulated genes (TPT1, LDHA,NCOA3,HIF1A,RAB13) and one down-regulated gene (ID1)were research by
real time quantitative PCR. Fourmore genes (BMP4, BMPR1B, SMAD1 and SMAD4) of the ID1 pathwaywere inves-
tigated and only one (BMPR1B) shows the same down regulation.
The data indicate the involvement of ANXA1Ac2-26 in the altered expression of genes involved in tumorigenic pro-
cesses, which could potentially be applied as a therapeutic indicator of cervical cancer.
© 2015 Elsevier B.V. All rights reserved.g,microgram;ACTB, beta-actin;
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Carcinoma of the cervix, or cervical cancer, is the second most fre-
quent neoplasm in women worldwide. Each year, approximately
530,000 new cases of cervical cancer arise. Cervical cancer is the fourth
leading cause of death in developing countries, with approximately
275,000 deaths per year (Jemal et al., 2011).
A factor directly related to cervical cancer is infection with human
papilloma virus (HPV), and approximately 90% of cervical cancer cases
are associated with HPV as a causative agent (Jaafar et al., 2009;
Walboomers et al., 1999). A common feature of this type of tumor is
the high expression of two oncogenes, E6 and E7, which encode multi-
functional proteins known for their ability to inactivate the tumor sup-
pressors p53 and pRb, respectively (Narisawa-Saito and Kiyono, 2007).
This altered expression of oncogenes leads to instabilities in the genome
by blocking the cell cycle and checkpoints deregulation in these cells,
due to the loss of these tumor suppressors genes. These cells then can
progress towards the tumorigenic process (Incassati et al., 2006).
Other factors that contribute to the risk of developing cervical cancer
have been described. These factors include age; the number of sexual
249J. Prates et al. / Gene 570 (2015) 248–254partners, which has been especially associated with co-infection;
prolonged use of hormonal contraceptives; a large number of full-
term pregnancies; and cigarette smoking (Soto-De Leon et al., 2011).
The inﬂammatory response is controlled by the action of anti-
inﬂammatory mediators, which act to maintain the homeostasis of the
immune response to prevent tissue damage. These mediators include
annexin-A1 (ANXA1), a 37 kDa protein expressed by tumor cells that
act as a modulator of inﬂammation (Flower, 1988; Silistino-Souza
et al., 2007; Alves et al., 2008).
The Annexins (ANX) are a well-conserved superfamily of structural-
ly related proteins characterized by a C-terminal homologous domain
containing four to eight repeats of 70–75 amino acids that are responsi-
ble for the calcium and phospholipid binding properties. The variable N-
terminal region is unique in length and sequence and includes potential
sites of phosphorylation, glycosylation and peptidase action (Gerke and
Moss, 2002). Annexins are present inmany organisms, includingmolds,
plants, fungi and mammals. They are preferentially localized in the
cytoplasm, where they associate with the plasma membrane or cyto-
skeleton, but some annexins, including ANXA1, have also been
found to localize to the outside of the plasma membrane (Solito
et al., 1994, 2003a). Though the function of the annexins is far from
clear, they have been shown to be involved in signal transduction
(Alldridge et al., 1999; De Coupade et al., 2000), vesicle transport
(Diakonova et al., 1997), cell transformation (Violette et al., 1990;
Solito et al., 1998), inﬂammation (Perretti and Gavins, 2003), cell
matrix interactions and apoptosis (Raynal and Pollard, 1994; Solito
et al., 2003b).
Annexin A1 (ANXA1), originally known as lipocortin 1, was the ﬁrst
member of this family to be cloned (Wallner et al., 1986). ANXA1
mimics the anti-inﬂammatory activity of glucocorticoids by inhibiting
the synthesis of eicosanoids and the activity of phospholipase A2
(PLA2), affecting the components of the inﬂammatory reaction and
the release of arachidonic acid (Flower, 1988; Perretti and Gavins,
2003). This protein is especially found in many cell types related to de-
fensive processes, which include neutrophils (Oliani et al., 2001), mast
cells (Oliani et al., 2008), eosinophils (Oliani et al., 2002) andmonocytes
(Goulding et al., 1990).
The expression and localization of ANXA1 have been investigated in
experimental models of acute inﬂammation induced by carrageenan in
the rat mesentery through the analysis of extravasated leukocytes
(Oliani et al., 2001; Gil et al., 2006). The vascular endothelium and
chronic granulomatous inﬂammation have also been examined in the
skin of mice (Oliani et al., 2008; Gibbs et al., 2002).
After it was discovered that the biological activity of ANXA1 could be
reproduced by the ﬁrst twenty-six amino acids in the N-terminus (pep-
tide Ac2-26) as well as some smaller peptides (Cirino et al., 1993;
Perretti et al., 2001), the use of thesemolecules in experimental models
of acute (Damazo et al., 2006; Gavins et al., 2007), chronic (Gibbs et al.,
2002) and systematic inﬂammation has become commonplace
(Damazo et al., 2005). The management of these mimetic ANXA1 pep-
tides causes the activation of the abundant ANXA1 receptors found in
leukocytes, promoting cell activation and intracellular signaling, pro-
voking detachment of adherent leukocytes (Gavins et al., 2003;
Gastardelo et al., 2009).
In comparison to HPV negative squamous cell penile carcinoma
samples, ANXA1 protein expression was signiﬁcantly increased in
high-risk HPV squamous cell penile carcinoma samples indepen-
dently of the subtype of penile squamous cell carcinoma. ANXA1 is
likely to play an oncogenic role in penile cancer associated with
high-risk HPVs (Calmon et al., 2013). By contrast, the ANXA1 expres-
sion in cervical carcinogenesis has been scarcely investigated. The
levels of this protein and its mRNA decrease as the cancer develops,
suggesting that ANXA1 may be regarded as a biological marker in
tumor progression (Lee et al., 2008). The down-regulation of
ANXA1 expression in [LaCit2]3 (Lanthanum citrate complex)-treat-
ed SiHa cells suggests that ANXA1 might regulate growth factorsrelated to apoptosis to mediate programmed cell death (Shen et al.,
2010).
Though the works related to ANXA1 have contributed to a greater
understanding of the role of this protein in inﬂammatory and tumor-
igenic process, the molecular mechanisms by which ANXA1 modu-
lates cellular responses in the inﬂammatory process have not yet
been fully determined. Available data suggest that this protein may
be signiﬁcantly involved in cancer in addition to its important role
in the inﬂammatory process, most likely through signaling cascades
that include genes related to the cell cycle, differentiation and
apoptosis.
To investigate the effects of ANXA1 in cervical cancer, we evaluat-
ed the inﬂuence of this peptide on the morphology, cell proliferation
and gene expression in SiHa cells. We also identiﬁed the signaling
pathways that genes modulated by ANXA1Ac2-26 participate which
are important for tumorigenic and the inﬂammatory process.
2. Materials and methods
2.1. SiHa culture conditions
The SiHa cell line originally established from an epidermoid carci-
noma of the cervix (ATCC, Rockville, Maryland, USA) was obtained
and seeded at a density of 1 × 106 cells/mL per 75 cm2 culture ﬂask
(Corning, NY, USA). MEM-Earle medium (Cultilab, Campinas, SP,
Brazil) was used at pH 7.5 and supplemented with 10% fetal calf
serum (Cultilab), 1% non-essential amino acids and 1% antibiotic/
antimycotic (Invitrogen Corporation, Carlsbad, CA, USA) and cul-
tured at 37 °C under an atmosphere of 5% CO2.
2.2. Pharmacological treatment
The SiHa cells were subdivided into a control group that was not
manipulated and an experimental group to which 3 μMof ANXA1Ac2-
26 was added. The experiments were conducted for time periods of 2,
4, 24, 48 and 72 h to determine the statistically signiﬁcant time for
further use in the methodology.
2.3. Growth curve
SiHa cells were seeded in triplicate at a density of 5 × 104 cells in
plastic 6-well plates and divided in two groups. The control group
was grown on complete medium whereas peptide ANXA1Ac2-26
was added to the experimental group. 24 h later, when the cells
had already adhered, SiHa cultures were incubated with serum free
medium (MEM 0%). After an additional 24 h, peptide was added to
the experimental group whereas the control group was maintained
in complete medium without any pharmacological manipulation.
The cell morphology was observed on each day. The cytotoxic ef-
fects of peptide on the proliferation of SiHa cells were investigated in
two experimental groups at 2, 4, 24, 48 and 72 h. The cells were har-
vested, stained with trypan blue and counted using a Neubauer he-
mocytometer. Signiﬁcant differences between the groups were
determined by one-way analysis of variance (one-way ANOVA) and
if found to be signiﬁcant, further analyzed using the Bonferroni
test. The same experiment was repeated twice.
2.4. RNA extraction for Rapid Subtraction Hybridization (RaSH) and real
time PCR experiments
SiHa cells were seeded at a density of 1 × 106 cells/mL in 75 cm2 cul-
ture ﬂasks in complete medium (control group) and incubated with
10 μg/mL of peptide Ac2-26 for 72 h (experimental group). The RNA
from control and ANXA1Ac2-26 treated SiHa cells was extracted using
Trizol (Sambrook and Russel, 2001) following treatment with DNase
(Invitrogen). cDNA synthesis was performed using a High Capacity
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to the manufacturer's instructions.Table 1
Primers for the interesting genes.
Primer Sequence
HIF1A right 5′ TCCTCACACGCAAATAGCTG 3′
HIF1A left 5′ TGCTCATCAGTTGCCACTTC 3′
ID1 right 5′ TAGTCGATGACGTGCTGGAG 3′
ID1 left 5′ AAACGTGCTGCTCTACGACA 3′
LDHA right 5′ GCCGTGATAATGACCAGCTT 3′
LDHA left 5′ TGGCAGCCTTTTCCTTAGAA 3′
NCOA3 right 5′ AAGTCCCCACACCTTCACTG 3′
NCOA3 left 5′ TTCTGGCAATACTGGGAACC 3′
RAB13 right 5′ CTGCAAAGCGAATGATCAGA 3′
RAB13 left 5′ AGCCTACGACCACCTCTTCA 3′
TPT1 right 5′ TAGAGCAACCATGCCATCTG 3′
TPT1 left 5′ GCTGCAGAACAAATCAAGCA 3′2.5. Rapid Subtraction Hybridization (RaSH)
The RaSH technique (Jiang et al., 2000) was performed with two
subtractions. The ﬁrst was termed “Sub I”, in which the SiHa control
cells were referred to as tester and the cells treated with peptide Ac2-
26 were termed driver. In the second subtraction, “Sub II,” the opposite
test was performed.
The ﬁrst cDNA strand was obtained by reverse transcriptase with
2 μL of oligo (dT) (50 mM) and 2 μL of 10 mM dNTPs at 65 °C for
5 min. The samples were immediately placed on ice for 1 min and
2.0 μL of 0.1 mM DTT, 1 μL of 40 U/μL RNAout and 4.0 μL of 5X First-
Strand Buffer [250 mM Tris–HCL (pH 8,3), 375 mM KCL and 15 mM
MgCL2] were added. The samples were incubated at 42 °C for 2 min be-
fore 1.0 μL of Superscript™ II reverse transcriptase (RT) (200 U/μL) was
added. Themixture was incubated again at 42 °C for 50min and then at
70 °C for 15min. Segments ofβ-actin cDNAwere also ampliﬁed to verify
the quality of these reactions.
The second strand of cDNA was synthesized in reactions containing
30 μL of 5X Second Strand Buffer, 3 μL of 10 mM dNTPs, 1 μL of DNA li-
gase (10 U/μL), 4 μL of DNA Pol I (10 U/μL) and 1.0 μL of RNase H (2 U/
μL). The samples were incubated for 2 h at 16 °C before the addition of
2 μL of T4 DNA Pol (5 U/μL) and further incubation for an additional
5 min. The action of T4 DNA Pol was inhibited by the addition of 10 μL
of 0.5 M EDTA. Phenol:chloroform extraction was used to purify the
sample and the pellet was resuspended in 45 μL of water. The cDNA
was used in ampliﬁcation reactions for segments of GAPDH and was
subsequently digestedwith 2 μL ofMboI enzyme (10U/μL) and incubat-
ed for 1 h at 37 °C. Finally, over 1 μL of this enzymewas added to the re-
action, and the samples were incubated overnight at 37 °C.
To this cDNA was added 4.1 and 4.5 μL, respectively, of the adaptors
XDPN-14 5′-CTGATCACTCGAGA and XDPN-12 5′-GATCTCTCGAGT
(Sigma Chemical, ﬁnal concentration 10 mM), 8 μL of 5X T4 DNA ligase
buffer Invitrogen©, heated at 55 °C for 1 min, and cooled down to 14 °C
within 1 h. The cDNA received 3 μL (9 U) of T4 DNA ligase (3 U/μL), liga-
tionwas carried out overnight at 14 °C. After phenol/chloroform extrac-
tion and ethanol/glycogen precipitation, the mixtures were diluted to
100 μL with TE buffer (10 mM Tris/1 mM EDTA); 40 μL of the mixtures
were used for PCR ampliﬁcation.
The PCR mixtures were set up using 10 μM XPDN-18 5′-CTGATCAC
TCGAGAGATC, 0.4 mM dNTPs, 10 × PCR buffer, 1.5 mMMgCl2 and 1 U
Taq DNA polymerase (Invitrogen). Thermocycler conditions were
1 cycle at 72 °C for 5 min, followed by 25 cycles of 94 °C for 1 min,
55 °C for 1 min, 72 °C for 1 min, ending in a ﬁnal extension at 72 °C
for 3 min. Ten microgram of puriﬁed PCR product (tester) was digested
with 10 U/μL XhoI (Invitrogen) for 6 h at 37 °C and followed phenol/
chloroform extraction and ethanol precipitation.
One-hundred nanograms of the tester cDNAweremixedwith 5 μg of
the driver cDNA in hybridization solution (0.5 M NaCl, 50 mM Tris/HCl,
SDS2% and 40% formamide) and, after heating at 99.9 °C for 5 min,
incubated at 42 °C for 1 h, and 42 °C for 48 h. After extraction and
precipitation, the hybridization mixture (1 μg) was ligated with
XhoI-digested pZero plasmid and transformed into competent
bacteria. Bacterial colonies were picked and used as DNA template
for PCR. Clones were sequenced using an automated DNA sequence
and homologies sequences were searched using the BLAST program.
Gene ontology (GO) annotation was used for the functional classiﬁ-
cation of up- and down-regulated genes using terms from Gene On-
tology database.
We further analyzed the genes through IPA (Ingenuity Systems©) to
relate the differentially expressed genes with biological functions and
processes in which these genes are involved and evaluate what the
main networks of interaction between them.2.6. Quantitative PCR — RT-qPCR
The RNA from control and ANXA1Ac2-26 treated SiHa cells was ex-
tracted and cDNA synthesis was performed as described above.
Six differentially expressed genes were selected for validation by
quantitative real time PCR experiments according to their direct or indi-
rect involvement in tumorigenesis. Their expression was checked in
treated samples relative to matched non-treated samples.
The primers were manually designed with: 19–23 bp length, 30–
80% GC content and a short amplicon size (80–120 bp). Their sequences
are available upon request (Table 1). Real time PCR was performed in
triplicate using a 7500 Fast Real-Time PCR System (Applied
Biosystems). Reaction mixture consisted of a 20 uL volume solution
containing 100-500 ηg of Power SYBR Green PCR Master Mix (Applied
Biosystems), 100 nM of each primer and 100 ng cDNA (control and
treated with peptide ANXA1Ac2-26 [3 μM]). The PCR conditions were
95 °C for 10 min followed by 40 cycles of 95° for 15 s and 60° for
1 min. Melting curve analysis was performed for each gene to check
the speciﬁcity and identity of the RT-PCR products.
For each primer set, the efﬁciency of the PCR reaction (linear equa-
tion: y = slope + intercept) was measured in triplicate on serial dilu-
tions of the same cDNA sample. The PCR efﬁciency (E) was calculated
by the formula E=[10(−1/slope)] and ranged from 1.96 to 2.02 in the dif-
ferent assays.
Two control genes (GAPDH, ACTB) were used as internal standards.
The relative expression ratio (fold change) of the target genes was cal-
culated according to Pffaﬂ (2001). Statistical analysis was performed
by a two-tailed unpaired t test using GraphPad prism software.
To investigate the pathway of ID1 gene, were analyzed four genes
(BMP4, BMPR1B, SMAD1 and SMAD4) following the methodology de-
scribed above. The ID1 gene is connected with more four genes
(BMP4, BMPR1B, SMAD1 and SMAD4) in TGF-Beta signaling pathway,
from KEGG (http://www.kegg.jp/pathway/ko04350), according to
Pathways from Biosystems (http://www.ncbi.nlm.nih.gov/gene/3397).
3. Results
3.1. Cellular morphology
SiHa cells were initially cultured and observed by phase contrastmi-
croscopy. These cells have a fusiform appearance and central core, with
multiple nucleoli and a eucromatic position,which are characteristics of
a cell with high metabolic activity (Fig. 1A). In cells treated with
ANXA1Ac2-26 [3 μM], there was no morphological change, and cytoplas-
mic processes were more clearly observed due to reduced cell prolifer-
ation (Fig. 1B).
3.2. Proliferation assay
In the proliferation assay, one-way ANOVA using the GraphPad
Prism 5 program was used to observe the growth inhibitory effect
Fig. 1.Morphological analysis and growth curve of ANXA1Ac2-26 peptide treatment in SiHa cell line. SiHa cells were seeded in complete MEM 10% at a concentration of 5 × 104 per well (6
well plate). The cell morphology observed in (A) the control group, characterized by a monolayer of nucleated cells was not altered in (B) the ANXA1Ac2-26 peptide [10 μg/mL] treated
group. 400× magniﬁcation. (C) SiHa cells were cultured, counted after 2, 4, 24, 48 and 72 h and these results were plotted on a growth curve. Assays were performed in triplicate.
Graph × = time (hours) and y = number of cells × 104. P values b 0.05 were signiﬁcant.
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proliferation in treated cells in comparison to the control group
(Fig. 1C). Statistical analysis showed that these differences were most
signiﬁcant (P ≤ 0,05) at a concentration of 10 μg/mL of peptide and a cul-
ture time of 72 h.
3.3. Genes identiﬁed using the RaSH approach
Rapid subtractive hybridization (RaSH) compares two distinct
experiments to ﬁnd differential gene expression. RaSH was performed
on SiHa cells from the control group and those treated with
ANXA1Ac2-26 for 72 h, and 82 clones were isolated and sequenced. By
screening these sequences through GenBank (Blast) and by rigorous
classiﬁcation and selection, 55 genes were found to be differentially
expressed. Two libraries of genes (Sub I and Sub II) were acquired.
Twenty-three genes of the “Sub I” library exhibited changes in expres-
sion levels in the control cells, whereas 32 genes of the “Sub II” library
changed in expression under treatment with peptide. Therefore, it was
expected that the gene expression of one library would be lower than
that of the other one. The libraries of the genes obtained along with
their different functions and processes described in the Gene Ontology
(GO) databases.
IPA (Ingenuity Systems©) was used to further analyze the 55 differ-
entially expressed genes, whichwere especially associated with tumor-
igenesis, apoptosis, necrosis and cell proliferation (Supplements 1 and
2). Moreover, some of these genes were chosen because they form a
network of important interactionswith other genes such asNF-kB,Ubiq-
uitin andHSP in the “Sub I” library or with genes associated with cancer,inﬂammatory diseases, the cell cycle, senescence, replication and cell
death in the “Sub II” library.
Six differentially expressed genes, TPT1, LDHA, ID1, NCOA3, HIF1A
and RAB13, were selected for validation by quantitative real time PCR
experiments (Table 1). These genes are associated with calcium ion
transport, cellular response to extracellular stimulus, apoptotic process,
regulation of transcription, response to hypoxia and regulating mem-
brane trafﬁcking, respectively and were chosen according to their func-
tions related to their direct or indirect involvement in tumorigenic and
inﬂammatory processes.
3.4. Real-time PCR validation of differentially expressed genes
The RaSH analysis indicated the down-regulation of four genes (ID1,
LDHA, RAB13 and TPT1) and up-regulation of two genes (HIF1A and
NCOA3) in SiHa cells treated with ANXA1Ac2-26. However, the quantita-
tive PCR experiment showed that only the expression of ID1was signif-
icantly reduced in these cells after peptide treatment (Fig. 2). The
expression of other genes oscillated without statistical signiﬁcance,
which was most likely because the peptide does not quantitatively
modify the expression of the selected genes despite its interaction
with the cell.
3.5. Real-time PCR gene-related pathway gene ID1
Four genes (BMP4, BMPR1B, SMAD1 and SMAD4) of ID1 pathway
were analyzed, however, the quantitative PCR experiment showed
that only the expression of BMPR1B was signiﬁcantly reduced in SiHa
Fig. 2. Quantitative real time PCR gene expression in SiHa cells treated with ANXA1Ac2-26
peptide. Expression ofHIF1A, ID1, LDHA,NCOA3, RAB13 and TPT1 genes in SiHa cells treated
with ANXA1Ac2-26 peptide (10 μg/mL), compared with control cells. Assays were per-
formed in triplicate to conﬁrm the results and the data represented in base 2 logarithm.
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The expression of other genes oscillated without statistical signiﬁcance
(BMP4, SMAD1 and SMAD4).
4. Discussion
Although cervical cancer can be prevented, it still represents amajor
public health problem for women, especially in underdeveloped coun-
tries where there is little monitoring and prevention.
The anti-inﬂammatory protein Annexin A1 (ANXA1) could be used
as an indicator of treatment. Though the literature on the in vitro
(D'Acquisto et al., 2008) and in vivo (Gastardelo et al., 2009; Facio
et al., 2011) pharmacological effects of this protein and its mimetic pep-
tides in inﬂammatory processes is extensive, the expression of this pro-
tein in cervical carcinogenesis has been scarcely investigated. Some
studies found the low expression of ANXA1 in cervical cancer, suggest-
ing that this protein could be considered a biological marker in the pro-
gression of invasive cervical cancer or regulates apoptosis-related
growth factors, point to a negative effect of ANXA1 in the cervical can-
cer, low expression worst prognostic (Lee et al., 2008; Shen et al.,
2010). Thus, we explored the action of ANXA1Ac2-26 on SiHa cells de-
rived from cervix squamous cell carcinoma, a cell line that provided
the best conditions for the experiments. These cells contained HPV16,
with an estimated 10 copies of HPV 16 DNA integrated into the cellular
DNA (Yee et al., 1985).
In analyzing the SiHa cell line, we observed that themorphology did
not change after treatment with peptide ANXA1Ac2-26. However, cell
proliferation decreased after 72 h of treatment. ANXA1 mediates the
disruption of normal cell morphology and inhibits cyclin D1 expression,
reducing cell proliferation through proximal modulation of the ERK sig-
nal transduction pathway (Alldridge and Bryant, 2003). ANXA1 has di-
rect anti-proliferative effects on cells possibly through the constitutiveFig. 3. Quantitative real time PCR gene expression in SiHa cells treated with ANXA1Ac2-26
peptide. Expression of BMP4, BMPR1B, SMad1 and SMad4 genes in SiHa cells treated with
ANXA1Ac2-26 peptide (10 μg/mL), compared with control cells. Assays were performed in
triplicate to conﬁrm the results and the data represented in base 2 logarithm.over-activation of ERK1/2. Thus, the anti-proliferative role of ANXA1
may be directly responsible, at least in part, for the growth arrest.
These ﬁndings suggest that ANXA1 may act as a tumor suppressor
(Ang et al., 2009).
But in the other hand, this anti-proliferative effect can be explained
by apoptosis too, Parente and Solito (2004) comment that ANXA1 pro-
motes inﬂammatory cell apoptosis associated with transient rise in in-
tracellular calcium and caspase-3 activation. Then in these SiHa cells,
how there are inﬂammatory cells in cancer process, we can suppose
that this negative effect can be explained by apoptosis (Parente and
Solito, 2004).
Apoptosis was also a criterion for selecting the differentially
expressed genes for validation by real-time RT-PCR. Of the 55 genes
identiﬁed by RaSH approach was very difﬁcult choose only six genes
to validation, because all of them have some interesting function, but
IPA (Ingenuity Systems©) was helpful to choose which genes were es-
pecially associated with tumorigenesis, apoptosis, necrosis, regulation
of transcriptional and in the same gene network.
After an analysis of the literature, six genes (HIF1A, ID1, LDHA,
NCOA3, RAB13 and TPT1) were selected for validation by real-time RT-
PCR using treated and non-treated cell lines. These genes show poten-
tial involvement in signaling cascades related to tumorigenesis and/or
the interaction between inﬂammation and tumor cells through angio-
genesis, metastasis, lactate dehydrogenase activity, regulation of gene
expression, cell adhesion and binding and calcium ion transport. The
RT-PCR results for the ID1 gene were consistent with the RaSH data.
For the gene expression ofNCOA3 andHIF1A, the resultswere not signif-
icantly increased. Thus, these genes can be considered to be good mo-
lecular markers if their high expression levels are conﬁrmed in other
cells. LDHA, RAB13 and TPT1 genes still require further testing. These re-
sults aremost likely due to the higher concentrations of the peptide that
are required in these cells to observe the mimetic effects.
The different expression levels of the ID1 gene are related to angio-
genesis, differentiation and metastasis. The overexpression of ID1 was
detected in esophageal squamous cell carcinoma, which suggests that
in our study, ANXA1may regulate this gene by decreasing its expression
andmay be used as a possible therapeutic target. ID1 belongs to a family
of smallmolecules of short length (13 to 20 kDa) and acts as an inhibitor
of differentiation or DNA binding (Benezra et al., 1990). The ID1 gene is
not a transcription factor, it is a transcriptional regulator (lacking a basic
DNA binding domain) which negatively regulates the basic helix-loop-
helix (bHLH) transcription factors by forming heterodimers and
inhibiting their DNA binding and transcriptional activity (Zheng et al.,
2004). Thus, ID1 regulates the effects of transcription factors on target
genes. Infection by high-risk human papilloma viruses (HPVs) is consid-
ered to be the central cause of invasive cervical cancer, suggesting that
high-risk HPVs can enhance the progression of human cervical cancer
through ID1 regulation (Darnel et al., 2010).
The overexpression of ID1 alone can induce angiogenic processes in
endothelial progenitor cells (EPCs) in ovarian cancer. The expression of
ID1 and matrix metalloproteinase-2 (MMP-2) was increased in EPCs
isolated from ovarian cancer patients compared to those obtained
from healthy subjects. It can thus be concluded that ID1 can enhance
EPC angiogenesis in ovarian cancer, which is mainly mediated by the
PI3K/Akt and NF-κB/MMP-2 signaling pathways (Su et al., 2013).
In most metastatic cancer patients, epithelial tumor cells from pri-
mary tumor samples express any grade ID1 positivity. In addition,
higher protein expression levels seem to correlate with poorer progno-
ses in prostate cancer (Ponz-Sarvisé et al., 2014). The overexpression of
ID1 protein is associated with more aggressive behavior of tumor cells
in human cervical cancer and is an independentmarker for the progres-
sion of this tumor type (Schindl et al., 2001).
The ID1 is considered as a BMP (bone morphogenetic protein) spe-
ciﬁc target gene that binds either to a type 1 or a type 2 receptor to
form the ternary signaling complex (Chang et al., 2002). BMPs belong
to the TGF-β superfamily and act via their speciﬁc receptors, the
253J. Prates et al. / Gene 570 (2015) 248–254BMPRs. Among the receptors, BMPR1B has been previously analyzed
and shown to be linked to the advancement of breast cancer and poor
prognosis. Analysis revealed lower expression levels of BMPR-IB tran-
script in poor prognosis patient samples compared to good prognosis
samples, as well as, down-regulation of BMPR-IB in MDA-MB-231cells
and leads to increased cell proliferation of breast cancer cells in vitro
(Bokobza et al., 2009). Probably the down expression of the BMPR1B re-
ceptor is according to the ID1 gene expression.
In the literature, the overexpression of ID1 gene is observed in cervi-
cal cancer, but our data showed decreased expression of ID1 and BMPR-
1B genes after the peptide treatment, suggesting that this peptide can
modify the expression of some genes in cervical carcinoma cells. As con-
sequence of the decreased expression of ID1 gene by the peptide, ID1-
targeted transcription factors will be relieved to regulate their down-
stream signals.
The genes evaluated in this study showed differential expression in
SiHa cells in amanner dependent onANXA1Ac2-26 treatment. In summa-
ry, this study highlights the importance of the RaSH technique as a fast
and efﬁcient method for identifying genesmodulated by ANXA1 in cells
of epithelial origin. Further experiments are needed to determine
whether other genes obtained by subtraction are regulated by ANXA1
and whether these are causally related to treatment-induced changes
in this protein. The functions of the genes identiﬁed in this study are im-
portant in tumor progression and are amenable to changes through al-
tering the metabolism of the cervical epithelial cells.
The cervix is difﬁcult to access, and treatments for cervical carcino-
ma commonly involve surgery, chemotherapy or radiotherapy. Howev-
er, new therapeutics such as the use of gene therapy associated with
nanoparticles tested in cervical cancer derived HeLa cells are being de-
veloped, allowing the delivery of drugs into target cells (Zheng et al.,
2013).
Finally, the ANXA1Ac2-26 peptide alters the proliferation and gene ex-
pression of SiHa cells. These changes are most likely related to inﬂam-
matory and tumorigenic processes. Thus, we suggest that the peptide
has modulatory effects on the metabolism of this cell type. Few investi-
gations have evaluated the effects of this peptide on the expression of
selected genes Our data suggests the mechanisms of action of this
anti-inﬂammatory protein, and future molecular studies must be con-
ducted to verify these processes. Our ﬁndings suggest the importance
of future studies using SiHa cells for the development of new therapies.
These studies should focus on gene activities that involve the action of
ANXA1 and applications of this peptide as a possible therapeutic in
the treatment cervical carcinoma.
5. Conclusions
These ﬁndings show that the ANXA1Ac2-26 alters the proliferation of
SiHa cells and the expression of genes with roles in signaling cascades
involved in the inﬂammatory and tumorigenic processes. Thus, our re-
sults point to possible applications of the ANXA1Ac2-26 peptide as an in-
dicator of innovative therapies for the treatment of cervical carcinoma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gene.2015.06.021.
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